In the volatility caused by policy convergence, the future belongs to organizations that can intelligently navigate inflection points that precede launch
In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity discusses how policy shifts are converging to compress pharma revenue opportunity and force decisive commercial choices much earlier in development. He highlights how IRA time horizons, Europe’s Joint Clinical Assessment, and MFN cross-border pricing dynamics are creating downstream constraints that multiply when they hit together making “best science” and “commercial excellence” alone insufficient. The new reality is that value is won or lost at a small number of irreversible decision points, so companies must move commercial thinking upstream into target selection, indication sequencing, evidence planning, protocol design, pricing architecture, and market entry strategy. Steve talks through four inflection points – early path-to-value, optimal development strategy, go-to-market configuration, and sustained value reinforcement – to help leaders anticipate evidence demands, plan for scenarios, and build value into assets before it’s too late to fix later.
Tune in to hear how the future of value creation is being reshaped, and why companies that prepare earlier will have a major strategic advantage!
Listen Now
"*" indicates required fields
